Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Early Access Treatment With Intracerebroventricular Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

NCT07733856 is registered in ClinicalTrials.gov with Spruce Biosciences as lead sponsor.

NCT NCT07733856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07733856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Early Access Treatment With Intracerebroventricular Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
Lead sponsor
Spruce Biosciences
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mps iiib (sanfilippo b syndrome), mucopolysaccharidosis type iiib